Endovascular approaches to acute stroke, part 1: Drugs, devices, and data.

  title={Endovascular approaches to acute stroke, part 1: Drugs, devices, and data.},
  author={R G Nogueira and Lee H Schwamm and J A Hirsch},
  journal={AJNR. American journal of neuroradiology},
  volume={30 4},
Despite years of research and pioneering clinical work, stroke remains a massive public health concern. Since 1996, we have lived in the era of US Food and Drug Administration-approved intravenous (i.v.) recombinant tissue plasminogen activator (rtPA). This treatment, despite its promise, continues to exhibit its limitations. Endovascular therapy has several theoretic advantages over i.v. rtPA, including site specificity, longer treatment windows, and higher recanalization rates. In this… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 52 extracted citations


Publications referenced by this paper.
Showing 1-10 of 116 references

: comparison of the catch thrombectomy device and the Merci Retriever in vivo

  • H Henkes, S Lowens, E Miloslavski
  • 2008

: final results of the Multi MERCI trial

  • W Yu, D Binder, A Foster-Barber
  • 2008

: results of an international phase III trial — Abciximab in Emergency Treatment of Stroke Trial ( AbESTT - II )

  • B Eckert, C Koch, G Thomalla
  • 2008

: the CLEAR stroke trial

  • HP Adams, MB Effron, J Torner
  • 2008

A novel, self expanding, fully retractable mechanical thromboembolectomy device for treatment of acute ischemic stroke

  • R. Jahan
  • Abstract presented at: 5th Annual Meeting of the…
  • 2008
1 Excerpt

Brott T, for the CLEAR Trial Investigators. The combined approach to lysis utilizing eptifibatide and rtPA in acute ischemic stroke: the CLEAR stroke trial

  • AM Pancioli, J Broderick
  • Stroke
  • 2008
1 Excerpt

Similar Papers

Loading similar papers…